About Envy Medical
Envy Medical is one of the most exciting medical technology companies to emerge in the field of dermatology and medical aesthetics. Founded by Ken Karasiuk, the Company flourished on the 2002 patented invention of Dermalinfusiom, method of non-invasive skin therapy, under the SilkPeel™ brand of medical devices. SilkPeel is already a gold standard for leading dermatologists and cosmetic surgeons for treating acne, hyperpigmentation, photo-damage, fine line wrinkles and minor scaring on the face and body.
Envy Medical also owns exclusive rights to a class of novel peptides that show clinical efficacy in the topical treatment of dermatologic indications. The lead peptide, decapeptide-12 was developed by Dr. Basil Hantash’s team of dermatological researchers out of Stanford University, this ground-breaking technology encompasses the only peptide class clinically shown to significantly brighten skin, and address hyperpigmentation. In 2010, the company introduced its first product line for skin brightening under the brand name Lumixyl™. Recent studies show that Lumixyl™, provides comparable or better results than prescription hydroquinone products, and yet is completely non-cytotoxic and therefore does not result in the side effects associated with such prescription level products.
The Future of Envy Medical
Envy Medical has already laid the foundation for powerful global growth with SilkPeel and Lumixyl Products now available in over 35 countries around the world. In fact, to the best of our knowledge, Lumixyl is on track to be the only “professional” skincare brand actively marketed in all 5 of the major global skincare markets (North America, Europe, Japan, China and Brazil) by mid-2013. Envy Medical is currently the owner or exclusive licensor of 13 patents covering a rich pipeline of specialize skin care treatment applicable to medical and consumer markets around the world.
You can find out more about Envy Medical Inc on their website here.